½ÃÀ庸°í¼­
»óǰÄÚµå
1150063

¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2022-2030³â)

Congestive Heart Failure Market Share, Size, Trends, Industry Analysis Report, By Product ; By End-Use; By Region; Segment Forecast, 2022 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 118 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 184¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü(Congestive Heart Failure) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä/½ÃÀå ±Ô¸ð ¹× ¿¹Ãø/µ¿Çâ/ÃËÁø ¿äÀΡ¤¾ïÁ¦ ¿äÀÎ/Á¦Ç°º°¡¤ÃÖÁ¾ ¿ëµµº°¡¤Áö¿ªº° ºÐ¼®/±â¾÷ °³¿ä µî ¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

  • ¸®Æ÷Æ® ¼³¸í
    • Á¶»çÀÇ ¸ñÀû
    • ½ÃÀå ¹üÀ§
    • ÀüÁ¦ Á¶°Ç
  • ÀÌÇØ°ü°èÀÚ

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • °³¿ä
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
  • Á¤º¸¿ø
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸

Á¦4Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå ÅëÂû

  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-»ê¾÷ ½º³À¼¦
  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå ¿ªÇÐ
    • ÃËÁø ¿äÀΰú ±âȸ
    • ¾ïÁ¦ ¿äÀΰú °úÁ¦
  • Porter¡¯s Five Forces
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡ÀÚÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ´ëüǰÀÇ À§Çù
    • ±âÁ¸ ±â¾÷ °£ÀÇ °æÀï·Â
  • PESTLE ºÐ¼®
  • ¿ïÇ÷¼º½ÉºÎÀüÀÇ »ê¾÷ µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19 ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå : Á¦Ç°º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü, Á¦Ç°º°(2018-2030³â)
  • ½É½Ç º¸Á¶ ÀåÄ¡
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ½É½Ç º¸Á¶ ÀåÄ¡º°, Áö¿ªº°(2018-2030³â)
  • À̽ÄÇü Á¦¼¼µ¿±â(ICD)
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, À̽ÄÇü Á¦¼¼µ¿±â(ICD)º°, Áö¿ªº°(2018-2030³â)
  • ÆäÀ̽º Á¦Á¶»ç
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÆäÀ̽º Á¦Á¶»çº°, Áö¿ªº°(2018-2030³â)
  • ½ÉÀå À絿±â ¿ä¹ý
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ½ÉÀå À絿±â ¿ä¹ýº°, Áö¿ªº°(2018-2030³â)
  • Ä«¿îÅÍ ÆÞ¼¼ÀÌ¼Ç µð¹ÙÀ̽º
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, Ä«¿îÅÍ ÆÞ¼¼ÀÌ¼Ç µð¹ÙÀ̽ºº°, Áö¿ªº°(2018-2030³â)

Á¦6Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • º´¿ø¡¤Å¬¸®´Ð
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, º´¿ø¡¤Å¬¸®´Ðº°, Áö¿ªº°(2018-2030³â)
  • ½ÉÇ÷°ü Áúȯ Àü¹® Ä¡·á ¼¾ÅÍ
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ½ÉÇ÷°ü Áúȯ Àü¹® Ä¡·á ¼¾Åͺ°, Áö¿ªº°(2018-2030³â)
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ¿Ü·¡ ¼ö¼ú ¼¾Åͺ°, Áö¿ªº°(2018-2030³â)

Á¦7Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀåÀÇ Æò°¡, Áö¿ªº°(2018-2030³â)
  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-ºÏ¹Ì
    • ºÏ¹Ì : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • ºÏ¹Ì : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¹Ì±¹
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-ij³ª´Ù
  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-À¯·´
    • À¯·´ : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • À¯·´ : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¿µ±¹
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-ÇÁ¶û½º
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-µ¶ÀÏ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-ÀÌÅ»¸®¾Æ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-½ºÆäÀÎ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-³×´ú¶õµå
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-·¯½Ã¾Æ
  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¾Æ½Ã¾Æ ÅÂÆò¾ç
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-Áß±¹
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-Àεµ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¸»·¹À̽þÆ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-ÀϺ»
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-Àεµ³×½Ã¾Æ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-Çѱ¹
  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-Áßµ¿¡¤¾ÆÇÁ¸®Ä«
    • Áßµ¿¡¤¾ÆÇÁ¸®Ä« : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • Áßµ¿¡¤¾ÆÇÁ¸®Ä« : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-»ç¿ìµð ¾Æ¶óºñ¾Æ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¾Æ¶ø ¿¡¹Ì¸®Æ® ¿¬¹æ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-À̽º¶ó¿¤
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-³²¾ÆÇÁ¸®Ä«
  • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-³²¹Ì
    • ³²¹Ì : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • ³²¹Ì : ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¸ß½ÃÄÚ
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-ºê¶óÁú
    • ¿ïÇ÷¼º½ÉºÎÀü ½ÃÀå-¾Æ¸£ÇîÆ¼³ª

Á¦8Àå °æÀï »óȲ

  • È®´ë¡¤Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • ÆÄÆ®³Ê½Ê/Çù¾÷/ÇùÁ¤/Àü½Ã

Á¦9Àå ±â¾÷ °³¿ä

  • ABIOMED
  • Berlin Heart
  • Abbot Laboratories
  • Aspect Imaging Ltd
  • Siemens
  • General Electric
  • Hitachi
  • Koninklijke Philips
  • Neusoft Corporation
  • ESAOTE
  • Medtronic
  • OMRON Corporation
  • Dexcom
  • Masimo
  • Jarvik Heart
  • Biotronik
  • Teleflex
  • Jude Medical
  • Lepu Medical
  • Osypka Medical GmbH
  • Medtronic
  • Boston Scientific Corporation
LYJ 22.11.30

The global congestive heart failure market size is expected to reach USD 18.48 billion by 2030, according to a new study by Polaris Market Research. The report "Congestive Heart Failure Market Share, Size, Trends, Industry Analysis Report, By Product (Cardiac Resynchronization Therapy, Counter Pulsation Devices, ICD, Pacemakers, Ventricular Assist Devices, Others); By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Congestive heart failure is becoming more prevalent, in part due to the rise in coronary artery disease and heart attacks worldwide. According to the World Health Organization's 2021 report, cardiovascular diseases (CVDs), which accounted for 17.9 million deaths worldwide in 2019 (32% of all fatalities), were the cause of 32% of all deaths. Furthermore, the American Heart Association predicts that by 2030, even more Americans than the present 22.2 million will have heart disease.

Due to the rising prevalence of CVDs and the increased need for treatment devices, the market will soon grow. Market leaders take part in new launches, partnerships, expansions, and acquisitions to stay competitive. For instance, Abbott's EnSite X EP System, which uses EnSite omnipolar technology to treat cardiac arrhythmias, received FDA approval in the U.S., in January 2022.

COVID-19 pandemic reportedly had a negative impact on people with underlying cardiovascular disease, particularly those who had previously experienced an acute cardiac injury. A research by Tarun Dalia et al., published in February 2021, found that congestive heart failure (CHF), which is present in individuals with COVID-19, is related to worse outcomes and higher mortality. Additionally, cardiac arrhythmia and abrupt cardiac injury are more likely to occur in people who have severe COVID-19 and non-survivor circumstances.

An increase in cardiovascular patients, an ageing population, insurance coverage, and technological developments like proprietary algorithms that accurately detect and reduce the incidence of atrial fibrillation are some of the main factors influencing the growth of implantable pacemakers. According to the United Nations Department of Economic and Social Affairs' research on world population ageing.

In 2020, there were 727 million people over the age of 65 in the world. Over the next three decades, the number of older people worldwide is predicted to more than quadruple, reaching over 1.5 billion in 2050. This is because an ageing population is more prone to chronic diseases, such as cardiovascular diseases, which are likely to increase during the projection period.

Congestive Heart Failure Market Report Highlights

In 2021, the market for congestive heart failure is expected to be dominated by pacemaker devices. Congestive heart failure therapeutic devices for the treatment of heart failure are in higher demand, pacemaker use is increasing, and pharmaceutical and medical device R&D are all contributing to the expansion of this market.

In 2021, hospital systems made up the majority of this market. This hospital segment has expanded as a result of the rising patient population and the significant concentration of trained workers in hospital settings. Additionally, hospitals support the reduction of adverse patient reactions during crucial medical procedures.

The majority of the market was controlled by North America. Rising cases of target illnesses, better public knowledge of the heart related ailments are few regional drivers.

The global players with global presence include ABIOMED, LivaNova, Jarvik Heart Inc., Berlin Heart, Abbot Laboratories, Aspect Imaging Ltd, CANON MEDICAL SYSTEMS CORPORATION, and Siemens.

Polaris Market Research has segmented the congestive heart failure market report based on product, end-use, and region:

Congestive Heart Failure, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Ventricular Assist Devices

Implantable Cardioverter Defibrillators (ICD)

Pacemakers

Cardiac Resynchronization Therapy

Counter Pulsation Devices

Congestive Heart Failure, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals and clinic

Specialized Cardiovascular Disease Treatment centers

Ambulatory surgery centers

Congestive Heart Failure, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Congestive Heart Failure Market Insights

  • 4.1. Congestive Heart Failure Market - Industry Snapshot
  • 4.2. Congestive Heart Failure Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of cardiovascular diseases (CVD)
      • 4.2.1.2. Growing geriatric population base
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of devices
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Congestive Heart Failure Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Congestive Heart Failure Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Congestive Heart Failure, by Product, 2018 - 2030 (USD Billion)
  • 5.3. Ventricular Assist Devices
    • 5.3.1. Global Congestive Heart Failure Market, by Ventricular Assist Devices, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Implantable Cardioverter Defibrillators (ICD)
    • 5.4.1. Global Congestive Heart Failure Market, by Implantable Cardioverter Defibrillators (ICD), by Region, 2018 - 2030 (USD Billion)
  • 5.5. Pacemakers
    • 5.5.1. Global Congestive Heart Failure Market, by Pacemakers, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Cardiac Resynchronization Therapy
    • 5.6.1. Global Congestive Heart Failure Market, by Cardiac Resynchronization Therapy, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Counter Pulsation Devices
    • 5.7.1. Global Congestive Heart Failure Market, by Counter Pulsation Devices, by Region, 2018 - 2030 (USD Billion)

6. Global Congestive Heart Failure Market, by End-Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
  • 6.3. Hospitals & Clinic
    • 6.3.1. Global Congestive Heart Failure Market, by Hospitals & Clinic, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Specialized Cardiovascular Disease Treatment Centres
    • 6.4.1. Global Congestive Heart Failure Market, by Specialized Cardiovascular Disease Treatment Centres, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Ambulatory Surgery Centres
    • 6.5.1. Global Congestive Heart Failure Market, by Ambulatory Surgery Centres, by Region, 2018 - 2030 (USD Billion)

7. Global Congestive Heart Failure Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Congestive Heart Failure Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Congestive Heart Failure Market - North America
    • 7.3.1. North America: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.3.3. Congestive Heart Failure Market - U.S.
      • 7.3.3.1. U.S.: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.3.4. Congestive Heart Failure Market - Canada
      • 7.3.4.1. Canada: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
  • 7.4. Congestive Heart Failure Market - Europe
    • 7.4.1. Europe: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.3. Congestive Heart Failure Market - UK
      • 7.4.3.1. UK: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.4. Congestive Heart Failure Market - France
      • 7.4.4.1. France: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.5. Congestive Heart Failure Market - Germany
      • 7.4.5.1. Germany: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.6. Congestive Heart Failure Market - Italy
      • 7.4.6.1. Italy: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.7. Congestive Heart Failure Market - Spain
      • 7.4.7.1. Spain: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.8. Congestive Heart Failure Market - Netherlands
      • 7.4.8.1. Netherlands: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.4.9. Congestive Heart Failure Market - Russia
      • 7.4.9.1. Russia: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
  • 7.5. Congestive Heart Failure Market - Asia Pacific
    • 7.5.1. Asia Pacific: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.5.3. Congestive Heart Failure Market - China
      • 7.5.3.1. China: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.5.4. Congestive Heart Failure Market - India
      • 7.5.4.1. India: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.5.5. Congestive Heart Failure Market - Malaysia
      • 7.5.5.1. Malaysia: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.5.6. Congestive Heart Failure Market - Japan
      • 7.5.6.1. Japan: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.5.7. Congestive Heart Failure Market - Indonesia
      • 7.5.7.1. Indonesia: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.5.8. Congestive Heart Failure Market - South Korea
      • 7.5.8.1. South Korea: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
  • 7.6. Congestive Heart Failure Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.6.3. Congestive Heart Failure Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.6.4. Congestive Heart Failure Market - UAE
      • 7.6.4.1. UAE: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.6.5. Congestive Heart Failure Market - Israel
      • 7.6.5.1. Israel: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.6.6. Congestive Heart Failure Market - South Africa
      • 7.6.6.1. South Africa: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
  • 7.7. Congestive Heart Failure Market - Latin America
    • 7.7.1. Latin America: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.7.3. Congestive Heart Failure Market - Mexico
      • 7.7.3.1. Mexico: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.7.4. Congestive Heart Failure Market - Brazil
      • 7.7.4.1. Brazil: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)
    • 7.7.5. Congestive Heart Failure Market - Argentina
      • 7.7.5.1. Argentina: Congestive Heart Failure Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Congestive Heart Failure Market, by Product, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. ABIOMED
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Berlin Heart
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Abbot Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Aspect Imaging Ltd
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Siemens
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. General Electric
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Hitachi
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Koninklijke Philips
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Neusoft Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. ESAOTE
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Medtronic
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. OMRON Corporation
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Dexcom
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Masimo
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Jarvik Heart
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Biotronik
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Teleflex
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development
  • 9.18. Jude Medical
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Development
  • 9.19. Lepu Medical
    • 9.19.1. Company Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Recent Development
  • 9.20. Osypka Medical GmbH
    • 9.20.1. Company Overview
    • 9.20.2. Financial Performance
    • 9.20.3. Product Benchmarking
    • 9.20.4. Recent Development
  • 9.21. Medtronic
    • 9.21.1. Company Overview
    • 9.21.2. Financial Performance
    • 9.21.3. Product Benchmarking
    • 9.21.4. Recent Development
  • 9.22. Boston Scientific Corporation
    • 9.22.1. Company Overview
    • 9.22.2. Financial Performance
    • 9.22.3. Product Benchmarking
    • 9.22.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦